Conditions: Juvenile Idiopathic Arthritis Associated Uveitis
Keywords: JIA
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
The investigators are doing this research study to see if tocilizumab (Actemra) is safe and effective when used for severe or refractory non-infectious uveitis. Uveitis is an inflammation of the eye that is caused by the body's immune system reacting against the eye tissues.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Tocilizumab
Intervention descriptions: intervention 1: Intravenous tocilizumab:

Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks

Protocol document: